Natural health products (NHPs) or complementary and
alternative medicine (CAM) are commonly used to prevent disorders or support the usual treatments of many diseases.
XP-828L, a
whey protein extract, has demonstrated potential benefits for the treatment of mild to moderate
psoriasis. The aim of this study was to analyze further clinical data that demonstrated the clinical benefits and safety of the
XP-828L in patients with
psoriasis and the potential mechanism of action of this product in vitro.
Oral administration (2.5 g, twice a day, over 112 days) of
XP-828L in 42 human subjects with mild to moderate
psoriasis improved their
PGA scores (physician's global assessment). Moreover, no significant changes in haematology or hepatic and renal parameters were observed throughout the study period, indicating the safety of the product. In vitro experiments showed that
XP-828L decreased the proliferation of
concanavalin A (ConA)-stimulated murine splenocytes and their production of
interleukin (IL)-2 and
interferon (IFN)-gamma. Although the in vivo mechanism of action of
XP-828L remains unknown,
XP-828L represents an NHP to be used as an alternative or concomitant treatment for mild to moderate
psoriasis and potentially for other immune-mediated diseases.